Seropositivity to Dengue, Zika, Yellow Fever, and West Nile Viruses in Senegal, West Africa., PMID:40207881
miRNome analysis reveals mir-155-5p as a protective factor to dengue infection in a resistant Thai cohort., PMID:39976655
Genetic diversity of dengue virus circulating in the Philippines (2014-2019) and comparison with dengue vaccine strains., PMID:39700304
Dominance of dengue virus serotype-2 in Pakistan (2023-2024): Molecular characterization of the envelope gene and exploration of antiviral targets., PMID:39557198
Efficacy and safety of Butantan-DV in participants aged 2-59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil., PMID:39116904
Epidemiological, virological and clinical characterization of a Dengue/Zika outbreak in the Caribbean region of Costa Rica 2017-2018., PMID:38988809
Development of optical and electrochemical immunodevices for dengue virus detection., PMID:38780022
Low-temperature culture enhances production of flavivirus virus-like particles in mammalian cells., PMID:38416210
Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults., PMID:38294972
Clinical, Virological, and Immunological Features in Cosmopolitan Genotype DENV-2-Infected Patients during a Large Dengue Outbreak in Sri Lanka in 2017., PMID:37696512
Epitope prediction and designing of receptor inhibitor of Dengue Envelope Protein: An in silico approach., PMID:37417165
Blockade-of-Binding Activities toward Envelope-Associated, Type-Specific Epitopes as a Correlative Marker for Dengue Virus-Neutralizing Antibody., PMID:37409936
Evolutionary dynamics of dengue virus in India., PMID:37011104
Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study., PMID:36888687
Efficient generation and characterization of chimeric dengue viral-like particles., PMID:36878035
Evaluation of an Immunoglobulin E Capture Enzyme-Linked Immunosorbent Assay for the Early Diagnosis of Dengue., PMID:36862827
The dengue virus 4 component of NIAID's tetravalent TV003 vaccine drives its innate immune signature., PMID:36734144
Recombinant Protein Mimicking the Antigenic Structure of the Viral Surface Envelope Protein Reinforces Induction of an Antigen-Specific and Virus-Neutralizing Immune Response Against Dengue Virus., PMID:36723792
Reactivity of DENV-positive sera against recombinant envelope proteins produced in bacteria and eukaryotic cells., PMID:36192522
Suppression of TGF-β/Smad2 signaling by GW788388 enhances DENV-2 clearance in macrophages., PMID:35596058
Sulfated β-glucan from Agaricus subrufescens inhibits flavivirus infection and nonstructural protein 1-mediated pathogenesis., PMID:35533778
Differential heterologous neutralisation profile against strains within DENV-3 genotype II., PMID:35225194
In-vitro antiviral action of Eupatorium perfoliatum against dengue virus infection: Modulation of mTOR signaling and autophagy., PMID:34509603
In Vitro Antiviral Activity of α-Mangostin against Dengue Virus Serotype-2 (DENV-2)., PMID:34069351
Co-Circulation of All Four Dengue Viruses and Zika Virus in Guerrero, Mexico, 2019., PMID:33944623
Generation and characterization of luciferase-secreting, single-round infectious DENV-2 reporter for functional antibody assays., PMID:33662412
Chimeric flavivirus enables evaluation of antibodies against dengue virus envelope protein in vitro and in vivo., PMID:33299049
DENV-3 precursor membrane (prM) glycoprotein enhances E protein immunogenicity and confers protection against DENV-2 infections in a murine model., PMID:33121347
Antibody-independent and dependent infection of human myeloid cells with dengue virus is inhibited by carrageenan., PMID:32866533
Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement., PMID:32305868
Immunodomination of Serotype-Specific CD4+ T-Cell Epitopes Contributed to the Biased Immune Responses Induced by a Tetravalent Measles-Vectored Dengue Vaccine., PMID:32300346
Aedes aegypti lachesin protein binds to the domain III of envelop protein of Dengue virus-2 and inhibits viral replication., PMID:32141690
Alanine Substitution Inactivates Cross-Reacting Epitopes in Dengue Virus Recombinant Envelope Proteins., PMID:32069839
Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor., PMID:32015557
The Dengue ED3 Dot Assay, a Novel Serological Test for the Detection of Denguevirus Type-Specific Antibodies and Its Application in a Retrospective Seroprevalence Study., PMID:30934772
Dynamics of nonstructural glycoprotein-1 in dengue patients presenting with different clinical manifestations from 1986 to 2012 in Rio de Janeiro, Brazil., PMID:30411369
Surveillance for Flaviviruses Near the Mexico-U.S. Border: Co-circulation of Dengue Virus Serotypes 1, 2, and 3 and West Nile Virus in Tamaulipas, Northern Mexico, 2014-2016., PMID:30226141
Establishment of Baculovirus-Expressed VLPs Induced Syncytial Formation Assay for Flavivirus Antiviral Screening., PMID:29997331
Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice., PMID:29976679
Molecular characterisation and phylogenetic analysis of dengue outbreak in Pasighat, Arunachal Pradesh, Northeast India., PMID:29735824
Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4., PMID:29593041
Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo., PMID:29367852
Safe Staphylococcal Platform for the Development of Multivalent Nanoscale Vesicles against Viral Infections., PMID:29253342
A DENV-2-type-specific monoclonal antibody binds to the DENV-complex-reactive antigenic site on envelope protein domain 3., PMID:28631593
Understanding Zika Virus Stability and Developing a Chimeric Vaccine through Functional Analysis., PMID:28174309
Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies., PMID:27301568
Characterization of two anti-dengue human monoclonal antibodies prepared from PBMCs of patients with dengue illness in Thailand., PMID:27265466
Synthetic B-Cell Epitopes Eliciting Cross-Neutralizing Antibodies: Strategies for Future Dengue Vaccine., PMID:27223692
Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection., PMID:27185081
Characterization of the 2013 dengue epidemic in Myanmar with dengue virus 1 as the dominant serotype., PMID:27154331
For research use only. Not for human or drug use.
